X
Xi-Tao Wang
Researcher at Bristol-Myers Squibb
Publications - 6
Citations - 211
Xi-Tao Wang is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Organic anion transporter 1 & Internalization. The author has an hindex of 3, co-authored 6 publications receiving 163 citations.
Papers
More filters
Journal ArticleDOI
Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression
David J. Donnelly,R. Adam Smith,Paul E. Morin,Dasa Lipovsek,Jochem Gokemeijer,Daniel Cohen,Virginie Lafont,Tritin Tran,Erin L. Cole,Martin C. Wright,Joonyoung Kim,Adrienne Pena,Daniel W. Kukral,Douglas D. Dischino,Patrick L Chow,Jinping Gan,Olufemi Adelakun,Xi-Tao Wang,Kai Cao,David Leung,Samuel J. Bonacorsi,Wendy Hayes +21 more
TL;DR: The feasibility of noninvasively imaging the PD-L1 status of tumors by small-animal PET studies is demonstrated by 18F-BMS-986192, which bound to tumor tissues as a function of PD- L1 expression determined by immunohistochemistry.
Journal ArticleDOI
Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression
Hong Shen,Tongtong Liu,Bridget L. Morse,Yue Zhao,Yueping Zhang,Xi Qiu,Cliff Chen,Anne Lewin,Xi-Tao Wang,Guowen Liu,Lisa J. Christopher,Punit Marathe,Yurong Lai +12 more
TL;DR: The findings revealed the important role of OAT2 in renal secretion and possible reabsorption of creatinine and suggested a molecular basis for potential species difference in the transporter handling of Creatinine.
Proceedings ArticleDOI
Abstract 1476: A therapeutic antibody that inhibits CD73 activity by dual mechanisms
Bryan C. Barnhart,Emanuela Sega,Aaron P. Yamniuk,Sandra V. Hatcher,Ming Lei,Haben Ghermazien,Anne Lewin,Xi-Tao Wang,Haichun Huang,Pingping Zhang,Alan J. Korman +10 more
TL;DR: Data supporting antibody-based anti-CD73 therapy in cancer and a novel mechanism for inhibition of CD73 enzymatic activity are presented that has potential for clinical application.
Proceedings ArticleDOI
Abstract 6694: Highly selective anti-CCR8 antibody-mediated depletion of regulatory T cells leads to potent antitumor activity alone and in combination with anti-PD-1 in preclinical models
Ruth Y. Lan,Amy Jhatakia,Joseph R Campbell,Nathan O. Siemers,Kai Lu,Mohammed Nasser,Tetiana Grigoriev,Priti B. Singh,Logan M Vlach,Tim Sproul,Chengyue Zhang,Xi-Tao Wang,Olufemi Adelakun,Felix Findeisen,Pavel Strop,Arvind Rajpal,Natalie Bezman,Michael Quigley,Renu Jain +18 more
TL;DR: The results support further clinical evaluation of CCR8 depletion in combination with immune checkpoint blockade as a novel immunotherapy for cancer.
Patent
Anticorps anti-ox40 et leurs utilisations
Zhehong Cai,Indrani Chakraborty,Marie-Michelle Navarro Garcia,Thomas D. Kempe,Korman Alan J,Alexander T. Kozhich,Hadia Lemar,Mark F. Maurer,Christina Maria Milburn,Michael Quigley,Maria Rodriguez,Xiang Shao,Mohan Srinivasan,Brenda L. Stevens,Thudium Kent B,Susan Chien-Szu Wong,Jochem Gokemeijer,Xi-Tao Wang,Han Chang,Christine Huang,Maria Jure-Kunkel,Zheng Yang,Yan Feng,Patrick Guirnalda,Nils Lonberg,Bryan C. Barnhart,Aaron P. Yamniuk,Karla A. Henning,Michelle Minhua Han,Ming Lei,Liang Schweizer,Sandra V. Hatcher,Arvind Rajpal,Praveen Aanur,Mark Selby +34 more
TL;DR: In this paper, a OX40-based method concerne des anticorps ou des parties de liaison a l'antigene de ceux-ci.